-
While not yet available in the United States, international researchers are examining use of contraceptive progestins in two birth control methods: a transdermal patch using gestodene and an oral contraceptive formulation using dienogest.
-
Look out in the waiting room of your clinic. How many patients are waiting to be seen by a provider to be tested for a sexually transmitted infection (STI)?
-
Wondering how to get prevention messages to adolescents? Public health officials are looking at new approaches such as text messaging on cell phones and Internet social networking sites to reach, educate, and engage teens regarding their sexual and reproductive health.
-
What is included in your practice during a first prenatal visit? If syphilis screening is not on the list, be sure to add it. Following a systematic review of current evidence, the U.S. Preventive Services Task Force has just reaffirmed its 2004 recommendation that clinicians screen all pregnant women for syphilis infection.
-
Are adolescents getting the care they need when it comes to reproductive health? According to a new policy statement issued by two committees of the American Academy of Pediatrics (AAP), underinsurance is an added barrier to teens' access to preventive, reproductive, and behavioral health care services.
-
According to a 2006 survey, about 12% of American women say they douche on a regular basis.
-
Human papillomavirus (HPV) is commonly found in young people in the United States, with as many as 18% of teenage girls testing positive for HPV.
-
How is your facility coping with the current economic downturn?
-
Take a look out into the waiting room of your family planning clinic. If you see an influx of patients, know that you are not alone. Planned Parenthood health centers across the country report an increase in patients who have lost their jobs, health insurance, or who no longer have the money to pay for medical care.
-
College health centers and certain family planning clinics who looked to reduced pricing on contraceptives from manufacturers had to regroup when the 2005 federal Deficit Reduction Act (DRA) tightened eligibility for nominally priced drugs.
